Obermatt
See Similar Stocks →

Flags

Earnings warning

ACADIA Pharmaceuticals

NSQ:ACAD · US0042251084
BiotechnologyMedium

360

80
EV / EBIT43
Price / Owner Earnings12
Owner Earnings Yield96
Dividend Yield1
Price/Sales77
EV / Gross Profit92
Price/Book46
Return on Capital83
Cash Return on Capital96
Return on Equity94
EBIT Margin62
Gross Profitability69
Accruals18
Owner Earnings Margin91
Sales growth62
Profit Growth72
Long-Term EPS Growth12
Reinvestment60
Price momentum43
Debt load68
Refinancing36
Debt Payback100
Liquidity—
Analyst ratings28
Opinion Changes50
Price Target Upside38
Market mood63
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ACADIA Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded1993
Employees877
Websiteacadia.com
ISINUS0042251084
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyChronic DiseasesArtificial IntelligenceGeneticsPsychiatryCentral Nervous SystemNeuroscienceBiotechnologyHealth CarePharmaceutical

Description

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company. The company has two core franchises in neurological and rare diseases. The company’s neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), w…

Analysis

Quality compounder

ACADIA Pharmaceuticals Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 9.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -4% a year, against analyst forecasts of -18%. The market is pricing in far more than analysts expect: heroic expectations.

Growth is tepid; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare ACADIA Pharmaceuticals with its peers
Abeona Therapeutics
NAQ:ABEO
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MBX Biosciences
NSQ:MBX
30
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Insmed
NSQ:INSM
51
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
—
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Nektar
NAQ:NKTR
4
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →